Neoadjuvant Osimertinib Achieves Major Pathological Responses With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC

According to findings published by OncLive, neoadjuvant osimertinib (Tagrisso), either as a single agent or in combination with chemotherapy, was associated with higher rates of major pathological response (MPR) in patients diagnosed with resectable non-small cell lung cancer (NSCLC) harboring EGFR mutations. The study compared the efficacy of osimertinib-based regimens to chemotherapy alone in the neoadjuvant (pre-surgical) setting. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor approved for the treatment of EGFR-mutated NSCLC. The results indicate that patients receiving osimertinib, either as monotherapy or combined with chemotherapy, experienced improved outcomes in terms of tumor response prior to surgery. These findings suggest a potential benefit of incorporating targeted therapy with or without chemotherapy in the neoadjuvant management of EGFR-mutated NSCLC. Further research and clinical trials may be necessary to confirm these results and to determine the long-term impact on survival and recurrence rates.